PAPPA2
Overview
PAPPA2 (Pappalysin 2) is a metalloproteinase involved in IGF signaling through cleavage of insulin-like growth factor binding proteins. Its role in cancer genomics is emerging; in NSCLC it has been identified as a gene preferentially mutated in tumors with durable clinical benefit from PD-1 blockade.
Alterations observed in the corpus
- Harbored deleterious mutations in ≥4 DCB patients and 0 NDB patients in a pembrolizumab NSCLC cohort; association not corrected for overall mutation burden and requires independent validation PMID:25765070
Cancer types (linked)
- NSCLC: Preferentially mutated in durable-clinical-benefit tumors on pembrolizumab PMID:25765070
Co-occurrence and mutual exclusivity
Therapeutic relevance
Open questions
- Association with pembrolizumab response is confounded by overall mutation burden elevation in DCB tumors and has not been independently validated PMID:25765070
Sources
This page was processed by crosslinker on 2026-05-14.